A meta-analysis covering more than 14 million procedures found several recovery advantages associated with da Vinci robotic surgery, while longer operating times and the study’s largely observational evidence base keep hospital economics central to the debate.
FDA clearance for Medtronic’s LigaSure RAS Maryland instrument adds a familiar vessel-sealing technology to Hugo, strengthening the company’s effort to build a broader robotic surgery ecosystem around instruments, procedures and recurring revenue.
Johnson & Johnson has received FDA De Novo authorization for the OTTAVA robotic surgical system across multiple upper-abdominal procedures. Its table-integrated design could bring robotic surgery into smaller operating rooms, but clinical evidence, surgeon training and hospital economics will determine whether it can challenge Intuitive Surgical.
Momentis Surgical wins FDA clearance for Anovo multiport surgery, widening its robotic platform while adoption and evidence remain key.
See how CONMED’s AirSeal expansion to da Vinci 5 hex cannulas could influence robotic surgery workflows, adoption and recurring sales.
Johnson & Johnson can launch its table-integrated Ottava surgical robot in the United States, opening a new competitive front against Intuitive Surgical and Medtronic.
Robotic surgery is opening up. Johnson & Johnson’s OTTAVA data may test whether hospitals want a new soft tissue platform.